N1-phenyl-N1-(((2R,4aS,5R,10bS)-5-phenyl-9-(trifluoromethyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinolin-2-yl)methyl)ethane-1,2-diamine | 1219814-75-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N1-phenyl-N1-(((2R,4aS,5R,10bS)-5-phenyl-9-(trifluoromethyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinolin-2-yl)methyl)ethane-1,2-diamine
• 英文别名: N'-[[(2R,4aS,5R,10bS)-5-phenyl-9-(trifluoromethyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinolin-2-yl]methyl]-N'-phenylethane-1,2-diamine
• CAS: 1219814-75-1
• 化学式: C₂₈H₃₀F₃N₃O
• 分子量: 481.561
• InChiKey: DPHOBSAVIIZAEE-DTBHQADXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  50.5
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  [(2R,4aS,5R,10bS)-5-phenyl-9-(trifluoromethyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinolin-2-yl]methyl methanesulfonate 、 N-苯基乙二胺 以 N-甲基吡咯烷酮 为溶剂， 反应 15.0h， 生成 N1-phenyl-N1-(((2R,4aS,5R,10bS)-5-phenyl-9-(trifluoromethyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinolin-2-yl)methyl)ethane-1,2-diamine
  参考文献：
  名称：

  The discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5

  摘要：

  Here we describe the discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5 originally found during a high-throughput screening (HTS) campaign sampling our in-house compound collection. The compounds optimized subsequently and characterized herein were potently inhibiting the ATPase activity of Kinesin-5 and also exhibited consistent cellular activity, in that cells arrested in mitosis and apoptosis induction could be observed. X-ray crystallographic data demonstrated that these inhibitors bind in an allosteric pocket of Kinesin-5 distant from the nucleotide and microtubule binding sites. The selected clinical candidate EMD 534085 caused strong growth inhibition in human tumor xenograft models using Colo 205 colon carcinoma cells at doses below 30 mg/kg administered twice weekly without showing severe toxicity as determined by loss of body weight. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.110

文献信息

• Substituted Tetrahydroquinolines
  申请人：Schiemann Kai

  公开号：US20080194615A1

  公开（公告）日：2008-08-14

  Disclosed are compounds of formula (I), wherein W, R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 have the meanings indicated in claim 1 . Said compounds can be used for the treatment of tumors, among other things.

  本发明揭示了式(I)的化合物，其中W、R、R1、R2、R3、R4、R5、R6和R7具有权利要求书中所示的含义。该化合物可用于肿瘤治疗等方面。
• US7893082B2
  申请人：——

  公开号：US7893082B2

  公开（公告）日：2011-02-22
• The discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5
  作者：Kai Schiemann、Dirk Finsinger、Frank Zenke、Christiane Amendt、Thorsten Knöchel、David Bruge、Hans-Peter Buchstaller、Ulrich Emde、Wolfgang Stähle、Soheila Anzali

  DOI：10.1016/j.bmcl.2010.01.110

  日期：2010.3

  Here we describe the discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5 originally found during a high-throughput screening (HTS) campaign sampling our in-house compound collection. The compounds optimized subsequently and characterized herein were potently inhibiting the ATPase activity of Kinesin-5 and also exhibited consistent cellular activity, in that cells arrested in mitosis and apoptosis induction could be observed. X-ray crystallographic data demonstrated that these inhibitors bind in an allosteric pocket of Kinesin-5 distant from the nucleotide and microtubule binding sites. The selected clinical candidate EMD 534085 caused strong growth inhibition in human tumor xenograft models using Colo 205 colon carcinoma cells at doses below 30 mg/kg administered twice weekly without showing severe toxicity as determined by loss of body weight. (C) 2010 Elsevier Ltd. All rights reserved.